Use of Intravenous Gadolinium-based Contrast Media in Patients with Kidney Disease and the Risk of Nephrogenic Systemic Fibrosis: Radiology In Training

A 66-year-old male patient with end-stage chronic kidney disease undergoing maintenance dialysis and with a history of group I intravenous gadolinium-based contrast media (GBCM) administration presented with clinical and pathologic findings consistent with nephrogenic systemic fibrosis. A summary of the evidence and recommendations for use of intravenous GBCM in patients with kidney disease is presented. (C) RSNA, 2021

Automated summary

A 66-year-old male patient with end-stage chronic kidney disease developed nephrogenic systemic fibrosis after receiving intravenous GBCM, highlighting the importance of carefully considering the use of contrast media in patients with kidney disease. The article provides a summary of evidence and recommendations for the use of intravenous GBCM in patients with kidney disease.